Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Pardi v. Tricida, Inc. et al
Case Number:
4:21-cv-00076
See also:
Court:
Nature of Suit:
Judge:
Firms
- Block & Leviton
- Bragar Eagel
- Latham & Watkins
- Levi & Korsinsky
- Pomerantz LLP
- Scott&Scott
- Sidley Austin
Companies
Government Agencies
Sectors & Industries:
-
October 24, 2025
Tricida Investors Win OK Of $14.2M Deal Over Kidney Drug
A California federal judge on Thursday granted final approval to a $14.2 million settlement that ends a class action against Tricida Inc. founder Gerrit Klaerner claiming he and the company misled investors on the approval chances for their new kidney disease drug, including nearly $4 million for plaintiffs' counsel.
-
March 13, 2024
Pharma Co. CEO Partly Beats Investor Suit Over Kidney Drug
A California federal judge has tossed for good some claims against Tricida Inc. CEO Gerrit Klaerner in a suit alleging he and the company misled inventors about the ability of Tricida's new kidney disease drug to gain regulatory approval, saying that many of Klaerner's challenged statements are opinions and that he didn't act with knowledge of wrongdoing.